ArticleJournal of virology1999
Protection against establishment of retroviral persistence by vaccination with a live attenuated virus.
Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Article
- Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection.PLoS pathogens · 2019Article
- Immunodominance of Adenovirus-Derived CD8Journal of virology · 2017Article
- Interference of retroviral envelope with vaccine-induced CD8Retrovirology · 2017Article
- Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery.Retrovirology · 2017Article
- CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells.Journal of virology · 2013Article
- Article
- Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses.PloS one · 2012Article
- Tissue-specific abundance of regulatory T cells correlates with CD8+ T cell dysfunction and chronic retrovirus loads.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Pirate primates in uncharted waters: lymphocyte transfers in unrelated, MHC-matched macaques.Current HIV research · 2009Review
- Allogeneic lymphocytes persist and traffic in feral MHC-matched mauritian cynomolgus macaques.PloS one · 2008Article
- Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.Journal of virology · 2005Article
- Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Novel role of CD8(+) T cells and major histocompatibility complex class I genes in the generation of protective CD4(+) Th1 responses during retrovirus infection in mice.Journal of virology · 2002Article
- CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection.Journal of virology · 2001Article
- Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV.BMC microbiology · 2001Article
- Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.Journal of virology · 2001Article
- Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.Journal of virology · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Many human viruses not only cause acute diseases but also establish persistent infections. Such persistent viruses can cause chronic diseases or can reactivate to cause acute diseases in AIDS patients or patients receiving immunosuppressive therapies. While the prevention of persistent infections is an important consideration in the design of modern vaccines, surprisingly little is known about this aspect of protection. In the current study, we tested the feasibility of vaccine prevention of retroviral persistence by using a Friend virus model that we recently developed. In this model, persistent virus can be detected at very low levels by immunosuppressing the host to reactivate virus or by transferring persistently infected spleen cells into highly susceptible mice. Two vaccines were analyzed, a recombinant vaccinia virus vector expressing Friend virus envelope protein and a live attenuated Friend virus. Both vaccines reduced pathogenic virus loads to levels undetectable by infectious center assays. However, only the live, attenuated vaccine prevented immunosuppression-induced reactivation of persistent virus. Thus, even very low levels of persistent Friend virus posed a significant threat during immunosuppression. Our results demonstrate that vaccine protection against establishment of retroviral persistence is attainable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.